Literature DB >> 16699809

The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.

S R Laviolette1, A A Grace.   

Abstract

Cannabinoids represent one of the most widely used hallucinogenic drugs and induce profound alterations in sensory perception and emotional processing. Similarly, the dopamine (DA) neurotransmitter system is critical for the central processing of emotion and motivation. Functional disturbances in either of these neurotransmitter systems are well-established correlates of the psychopathological symptoms and behavioral manifestations observed in addiction and schizophrenia. Increasing evidence from the anatomical, pharmacological and behavioral neuroscience fields points to complex functional interactions between these receptor systems at the anatomical, pharmacological and neural systems levels. An important question relates to whether these systems act in an orchestrated manner to produce the emotional processing and sensory perception deficits underlying addiction and schizophrenia. This review describes evidence for functional neural interactions between cannabinoid and DA receptor systems and how disturbances in this neural circuitry may underlie the aberrant emotional learning and processing observed in disorders such as addiction and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699809     DOI: 10.1007/s00018-006-6027-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  63 in total

1.  Inactivation of the basolateral amygdala during opiate reward learning disinhibits prelimbic cortical neurons and modulates associative memory extinction.

Authors:  Ninglei Sun; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2012-03-21       Impact factor: 4.530

Review 2.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

3.  Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Authors:  Chiayu Q Chiu; Nagore Puente; Pedro Grandes; Pablo E Castillo
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

4.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 5.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

6.  Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.

Authors:  Pankaj Pandey; Narayan D Chaurasiya; Babu L Tekwani; Robert J Doerksen
Journal:  Biochem Pharmacol       Date:  2018-06-26       Impact factor: 5.858

Review 7.  Selective MAO-B inhibitors: a lesson from natural products.

Authors:  Simone Carradori; Melissa D'Ascenzio; Paola Chimenti; Daniela Secci; Adriana Bolasco
Journal:  Mol Divers       Date:  2013-11-12       Impact factor: 2.943

8.  Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Authors:  Julie A Przybyla; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-12-16       Impact factor: 4.030

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 10.  Endogenous cannabinoid signaling at inhibitory interneurons.

Authors:  Thomas J Younts; Pablo E Castillo
Journal:  Curr Opin Neurobiol       Date:  2013-12-28       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.